A randomized open label multi-center study to compare immunogenicity and safety of BBIL's ROTAVAC to GSK's ROTARIX rotavirus vaccine when administered orally to infants aged 6-8 weeks.

Next Previous
Trial Profile

A randomized open label multi-center study to compare immunogenicity and safety of BBIL's ROTAVAC to GSK's ROTARIX rotavirus vaccine when administered orally to infants aged 6-8 weeks.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs ORV 116E (Primary) ; RIX 4414
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors Bharat Biotech

    • Most Recent Events

    • 25 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top